These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 19448401)

  • 1. The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERalpha negative breast cancer.
    Ford CE; Ekström EJ; Howlin J; Andersson T
    Cell Cycle; 2009 Jun; 8(12):1838-42. PubMed ID: 19448401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
    Ford CE; Ekström EJ; Andersson T
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility.
    Säfholm A; Tuomela J; Rosenkvist J; Dejmek J; Härkönen P; Andersson T
    Clin Cancer Res; 2008 Oct; 14(20):6556-63. PubMed ID: 18927296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of Wnt-5a expression in primary breast cancer is extended to premenopausal women.
    Sand-Dejmek J; Ehrnström R; Berglund P; Andersson T; Ryden L
    PLoS One; 2013; 8(8):e70890. PubMed ID: 23990917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retracted manuscript: The WNT-5a derived peptide, Foxy-5, possesses dual properties that impair progression of ERα negative breast cancer.
    Andersson T; Ford CE; Ekström EJ; Howlin J
    Cell Cycle; 2011 Apr; 10(7):1167. PubMed ID: 21430443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WNT-5A triggers Cdc42 activation leading to an ERK1/2 dependent decrease in MMP9 activity and invasive migration of breast cancer cells.
    Prasad CP; Chaurasiya SK; Axelsson L; Andersson T
    Mol Oncol; 2013 Oct; 7(5):870-83. PubMed ID: 23727359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival.
    Dejmek J; Leandersson K; Manjer J; Bjartell A; Emdin SO; Vogel WF; Landberg G; Andersson T
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):520-8. PubMed ID: 15701836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells.
    Säfholm A; Leandersson K; Dejmek J; Nielsen CK; Villoutreix BO; Andersson T
    J Biol Chem; 2006 Feb; 281(5):2740-9. PubMed ID: 16330545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine phosphorylation of transcriptional coactivator WW-domain binding protein 2 regulates estrogen receptor α function in breast cancer via the Wnt pathway.
    Lim SK; Orhant-Prioux M; Toy W; Tan KY; Lim YP
    FASEB J; 2011 Sep; 25(9):3004-18. PubMed ID: 21642474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines.
    Pukrop T; Klemm F; Hagemann T; Gradl D; Schulz M; Siemes S; Trümper L; Binder C
    Proc Natl Acad Sci U S A; 2006 Apr; 103(14):5454-9. PubMed ID: 16569699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas.
    Jönsson M; Dejmek J; Bendahl PO; Andersson T
    Cancer Res; 2002 Jan; 62(2):409-16. PubMed ID: 11809689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
    Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
    Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction and transport of Wnt 5a during macrophage-induced malignant invasion is mediated by two types of extracellular vesicles.
    Menck K; Klemm F; Gross JC; Pukrop T; Wenzel D; Binder C
    Oncotarget; 2013 Nov; 4(11):2057-66. PubMed ID: 24185202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt-5a is a synaptogenic factor with neuroprotective properties against Aβ toxicity.
    Varela-Nallar L; Parodi J; Farías GG; Inestrosa NC
    Neurodegener Dis; 2012; 10(1-4):23-6. PubMed ID: 22261402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
    Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
    Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
    Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
    Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
    Motomura K; Ishitobi M; Komoike Y; Koyama H; Nagase H; Inaji H; Noguchi S
    Oncology; 2010; 79(1-2):55-61. PubMed ID: 21071990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.